| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biophys J, March 2001, p. 1031-1032, Vol. 80, No. 3
Department of Chemical Engineering, Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104 USA
The coagulation pathway of blood is an ancient
mechanism to stop leaks of fluid from an organism. At sites of
damaged vascular endothelium, platelets and neutrophils are captured
from the flow stream while tissue factor on the wall can bind factor
VIIa to initiate a cascade of coagulation reactions on cellular
surfaces, resulting in the conversion of prothrombin to thrombin. The
thrombin cleaves fibrinogen to an active monomer that polymerizes to
form a fibrin meshwork. Physiologically, convection of oxygenated blood alleviates severe diffusion limitations that would otherwise exist in
the absence of flow (i.e., blood clots would cause heart attack and
stroke). Despite more than a century of brilliant research in blood
biochemistry, platelet and vascular wall biology, suspension rheology,
and transport physics, the complexity of blood clotting under flow has
prevented quantitative and predictive modeling. For example, given
non-anticoagulated whole blood of a defined genotype flowing at a fixed
wall shear rate over a defined reactive surface, it had been impossible
to predict the instantaneous rate or final extent of platelet,
neutrophil, and fibrin deposition. In this issue, Kuharsky and Fogelson
(2001) By flowing isolated platelets, neutrophils, or monocytes over defined
adhesive ligands attached to surfaces, many laboratories have measured
the shear stress dependency of transient pausing/rolling or firm
arrest. However, these studies require elimination of thrombin, which
activates platelets, as well as prevention of fibrin formation, which
stabilizes platelet deposits. The kinetics of the coagulation cascade
assembly on activated platelets (Mann et al., 1992 To tackle the intertwined biochemistry, cell biology, and
transport biophysics, Kuharsky and Fogelson assumed the existence of a
thin, well-mixed layer near the surface. Transport of species from
whole blood into this layer was then quantified by an overall mass
transfer coefficient, thereby eliminating the need to solve for
spatially dependent fluxes due to axial convection and radial dispersion. This insightful approach allowed the authors to solve 59 ordinary differential equations to simulate flowing human blood coagulating on a reactive wall via tissue factor initiation of the
extrinsic pathway. The one catch is that the use of this well-mixed layer embeds the flow physics into the reaction kinetics. For example,
the thickness h of this well-mixed layer depends on
velocity. When surface densities (fmol/cm2) are
homogenized into the shell volume of height h, the
new volumetric concentrations (and thus reaction rates) depend
moderately on the flow velocity of the simulation.
Poised between states of flowing liquid and solid clot, the stability
of blood is predicted to be balanced on the head of a pin (or, more
literally, a pin-prick). Increasing the tissue factor surface density
from 2 to 8 fmol/cm2 (50 sites/µm2) is predicted to cause a 4- to
5-order of magnitude explosion in the local thrombin concentration at
physiological shear rates. Given this sensitivity, a captured
neutrophil or monocyte presenting only 100 active tissue factor
molecules on its surface may have important consequences in sustaining
the coagulation process (Palabrica et al., 1992 Mechanisms of tissue factor inhibition (platelet coverage versus tissue
factor pathway inhibitor) were tested through the Kuharsky-Fogelson
model. Hemophilias A and B provide the clinical experimental situation
wherein factors VIII and IX are deficient. In order to simulate
impaired coagulation after display of tissue factor to factor VIII- or
IX-deficient blood, an additional physical mechanism was
required The Kuharsky-Fogelson model provides support for a fundamental insight:
platelet coverage of damaged wall leads to the quenching of
tissue-factor-mediated thrombosis. Although not modeled, fibrin deposits may have a similar effect if factor X must diffuse through the
fibrin to the tissue factor:VIIa complex at the surface. The authors
support a role for the intrinsic pathway (IXa-tenase) to continue
thrombosis after the first layer of platelets are deposited over the
tissue factor. Blood-borne tissue factor may also serve this purpose
(Giesen et al., 1999 Outside-in signaling alters the activation and adhesive state of the
platelet. As a platelet is activated it can release ADP and
thromboxane, both potent autocatalytic molecules. These interactions are captured to a first approximation through an experimentally derived
rate constant for the interaction of activated platelets with
unactivated platelets in a shear field. However, the magnitude of the
flow will influence the local levels of these highly diffusive platelet
release products. Also, the rates of successful cell-cell collisions,
cell-surface collisions, and fragmentation all depend on prevailing
flow conditions. When the receptor-ligand bond mechanics become better
characterized, the single rate constant for platelet deposition used in
the Kuharsky-Fogelson model may eventually be predicted for any set of
prevailing shear rates, platelet receptor levels, and surface ligand densities.
Human blood represents a real testing ground for functional genomics.
As a tissue, blood is easily obtained and has many well-defined genetic
mutations leading to various bleeding or clotting phenotypes. However,
blood is a tissue whose function is always dependent on the prevailing
hemodynamics. Quantitative modeling of blood function under flow will
have numerous diagnostic and therapeutic uses. The model of Kuharsky
and Fogelson is a dramatic advancement toward the development of
virtual blood, in which clotting for a genetic and pharmacological
background can be simulated in an appropriate fluid mechanical context.
![]()
ARTICLE
have launched the first full simulation of platelet activation,
deposition, and cell- and wall-dependent coagulation cascade activation
during blood flow over a tissue-factor-containing surface.
) and multicellular
aggregation in shear flow (Laurenzi and Diamond, 1999
) have both been
modeled; however, these models cannot handle spatial gradients that
occur during clotting on the wall.
).
platelet deposition blocking access of blood to the tissue
factor on the surface. In fact, the model predicted the increased
bleeding severity of hemophilia A over hemophilia B. Importantly, the
model passed an additional test in that it predicted impaired
coagulation under flow for blood with reduced platelet counts, as seen
in thrombocytopenia. On the opposite end of the spectrum of
blood performance, a future test of the model will be its ability
to predict the factor V Leiden phenotype, a clotting disorder due to a
mutated factor V that is resistant to inactivation by activated
protein C.
), and quantitative simulation will be useful in
evaluating these issues.
| |
FOOTNOTES |
|---|
Received for publication 17 January 2001 and in final form 17 January 2001.
Address reprint requests to Scott L. Diamond, Department of Chemical Engineering, Institute for Medicine and Engineering, 1024 Vagelos Research Laboratories, University of Pennsylvania, Philadelphia, PA 19104. Tel.: 215-573-5702; Fax: 215-573-7227; E-mail: sld{at}seas.upenn.edu.
| |
REFERENCES |
|---|
Biophys J, March 2001, p. 1031-1032, Vol. 80, No. 3
© 2001 by the Biophysical Society 0006-3495/01/03/1031/02 $2.00
This article has been cited by other articles:
![]() |
C. J. Kastrup, F. Shen, M. K. Runyon, and R. F. Ismagilov Characterization of the Threshold Response of Initiation of Blood Clotting to Stimulus Patch Size Biophys. J., October 15, 2007; 93(8): 2969 - 2977. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.C. Kuenen, M. Levi, J.C.M. Meijers, V.W.M. van Hinsbergh, J. Berkhof, A.K. Kakkar, K. Hoekman, and H.M. Pinedo Potential Role of Platelets in Endothelial Damage Observed During Treatment With Cisplatin, Gemcitabine, and the Angiogenesis Inhibitor SU5416 J. Clin. Oncol., June 1, 2003; 21(11): 2192 - 2198. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |